The government would like to see your marketing plan

Share this article:
A bill drafted by Rep. Henry Waxman (D-CA) and Rep. Ed Markey (D-MA) would require preclearance of all drug advertising, empower FDA to impose a moratorium on DTC advertising for up to three years after a drug is approved and require companies to present their marketing plans for drugs on demand. Washington wags are already calling the “Enhancing Drug Safety and Innovation Act of 2007” “Kennedy/Enzi on steroids,” after a similar bill sponsored by Sens. Kennedy (D-MA) and Enzi (R-WY). The Waxman/Markey bill would: *require that labeling and consumer ads for new drugs include a “unique symbol” indicating newly-approved status for the first two years after approval “or for such period as the Secretary determines on a case-by-case basis to be appropriate;” *”Require that the applicant submit to the Secretary advertisements of the drug for preclearance, if the Secretary determines that such preclearance is necessary,” to be reviewed within 45 days of submission; *Empower the secretary to require that ads for a particular drug carry “specific disclosures” of the date the drug was approved, noting that “existing information may not have identified or allowed for full assessment of all serious risks of using the drug,” or warnings about a particular “serious adverse event” listed in the labeling; *Allow for a temporary moratorium on consumer ads for a new drug “not to exceed 3 years;” *Empower the secretary to require that manufacturers submit a marketing plan for a given drug “as to allow the Secretary to determine whether any of the proposed or ongoing marketing activities undermine any of the requirements of the risk evaluation and mitigation strategy.” Other sections of the legislation deal with advancing the FDA’s Critical Path initiative and establishing clinical trial registry and results databases. John Kamp, executive director of the Coalition for Healthcare Communications, said a blanket ban on DTC would violate the First Amendment. “The Supreme Court has never approved censorship as a way to promote an informed population,” said Kamp. “Ignorance is never preferable to education. Congress should never force Congressman Markey to submit his often pithy remarks to a censor before he is allowed to utter them, nor should Congress silence drug companies until some censor can pass judgement.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...